Will Apelvis be reimbursed by medical insurance in 2024?

Apelixis is a breast cancer treatment drug produced by Novartis and approved by the U.S.FDA. It is classified as a PI3K inhibitor and blocks the growth of cancer cells by inhibiting the PI3K pathway. Its efficacy has been demonstrated in patients with certain types of breast cancer, and its combination with fulvestrant can significantly extend progression-free survival. The combination was particularly effective in patients who progressed after endocrine therapy, suggesting its role in later treatment. At present, the medical insurance issue of Apelix is u200bu200bthe focus of many patients. So by 2024, will Apelvis be reimbursed by medical insurance?

When discussing whether Apelvis can be reimbursed through medical insurance, it is first necessary to clarify the basic principles of the medical insurance policy. Medical insurance reimbursement policies usually only apply to drugs that have been marketed in the country and approved by the Food and Drug Administration. At present, Apelvis has not been approved for marketing by the China Food and Drug Administration, so it does not fall within the scope of medical insurance drugs. This means that under the current medical insurance policy, patients cannot pay for Apelvis directly through medical insurance reimbursement.

However, this does not mean that patients do not have treatment options. Although Apelis has not yet been launched in China, in other countries, such as India and Laos, relatively affordable original drugs and generic drugs are available.

In the Indian market, the price of the original Apelis drug is about 5,000 yuan per box, while in Laos, the price of the Lucius version of the generic drug is as low as more than 2,000 yuan per box. This provides new treatment options for patients with limited financial resources.

However, it is worth noting that when choosing these drugs, patients must purchase them through formal channels and pay attention to identify the authenticity of the drugs. When purchasing generic drugs, patients should know key information such as the drug's manufacturer and approval number to ensure the quality and safety of the drug.

In summary, although Apelvis is currently not reimbursable by medical insurance, patients still have other treatment options. By purchasing relatively affordable drugs through formal channels, patients can reduce their financial burden to a certain extent and at the same time obtain effective treatment.